Nepsone Pharmaceuticals is a Nordic biotech company developing first-in-class neuropeptide therapies for immune-mediated diseases. Our lead program, NS01, is designed to restore balance in the skin’s neuro-immune system and provide durable control of psoriasis with first clinical trails planned for Q3 2026. By targeting disease-driving nerve–immune crosstalk rather than broadly suppressing the immune system, we aim to deliver effective treatment with a cleaner safety profile and fewer systemic side effects. Our team brings deep experience in dermatology, peptide chemistry and translational drug development to move NS01 efficiently from bench to bedside.